- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
9.—(1) Schedule 1 to the 2015 Order (which specifies the controlled drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies) is amended as follows.
(2) In paragraph 1(a) of Part 1(1)—
(a)after “Cannabinol” insert “(not being the product specified in paragraph 10(1) or (2))”;
(b)after “Cannabinol derivatives not being dronabinol or its stereoisomers” insert “(and not being the product specified in paragraph 10(1) or (2))”;
(c)for “Cannabis (not being the substance specified in paragraph 4 of Part 2 of this Schedule)”, substitute “Cannabis (not being the substance specified in paragraph 9 or product specified in paragraph 10(1) or (2))”; and
(d)after “Cannabis resin” insert “(not being the product specified in paragraph 10(1) or (2))”.
(3) In Part 2 (which specifies controlled drugs excepted from Part 1), after paragraph 9 insert—
“10.—(1) A cannabis-based product for medicinal use in humans.
(2) A product which is—
(a)specified in Part 1 as a consequence of the application of paragraphs 2 to 5 to a preparation or other product (not being the substance specified in paragraph 9) which is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers); and
(b)produced for medicinal use in humans.
(3) In this paragraph—
“cannabis-based product for medicinal use in humans” means a preparation or other product (not being the substance specified in paragraph 9), which—
is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers);
is produced for medicinal use in humans; and
is—
a medicinal product, or
a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product; and
“medicinal product” has the same meaning as in the Human Medicines Regulations 2012(2).
(4) In this Schedule, “dronabinol” does not include any substance which—
(a)has the international non-proprietary name dronabinol (recommended by the World Health Organisation); and
(b)is derived from cannabis, cannabis resin or their constituents,
and stereoisomers of dronabinol are to be construed accordingly.”.
Paragraph 1 has been amended by S.I. 2017/632.
S.I. 2012/1916. See the definition of “medicinal product” in regulation 2.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: